In a nutshell The authors evaluated immune system-related adverse events and outcomes in melanoma patients treated with nivolumab (Opdivo). Some background In the advanced stage of melanoma (stage 3/4), cancer spreads from the skin to other parts of the body. Immunotherapy is a promising treatment option in advanced melanoma....
Read MoreTreatment(s) already received-Immunotherapy Posts on Medivizor
Ipilimumab-induced hypophysitis in advanced melanoma
In a nutshell The authors analyzed the occurrence, management and risk factors of hypophysitis (a complication of the immune system following ipilimumab [Yervoy] therapy) in advanced melanoma patients. Some background In advanced melanoma (stage III/IV), cancer spreads rapidly from the skin to other parts of the body....
Read MoreLong-term survival in advanced melanoma–benefit of ipilimumab and dacarbazine
In a nutshell The authors analyzed the 5-year survival rate in advanced melanoma patients treated with a combination of ipilimumab (Yervoy) and dacarbazine (DTIC, DTIC-Dome) in a phase III clinical trial. Some background In advanced melanoma (stage III/IV), cancer spreads from the skin to other parts of the...
Read MoreImmunotherapy in advanced melanoma: a review
In a nutshell The authors reviewed different immunotherapies for advanced melanoma. Some background In advanced melanoma (stage III/IV), cancer spreads from the skin to other parts of the body. Immunotherapy is a common treatment used in advanced melanoma. It uses the body’s own immune system to fight cancer. This...
Read MoreHow safe and effective is retreatment with ipilimumab in advanced melanoma?
In a nutshell The authors analyzed the effectiveness and safety of retreatment with ipilimumab (Yervoy) in patients with advanced melanoma. Some background The survival rate in advanced melanoma is poor. Ipilimumab, an immunotherapy (treatment that uses the body’s own immune system to fight cancer), is an...
Read MoreNivolumab compared to chemotherapy in patients with advanced melanoma
In a nutshell The objective of this study was to evaluate the safety and effectiveness of nivolumab (Opdivo) as secondary treatment in advanced melanoma. Some background In the advanced stage of melanoma (stage III/IV), cancer spreads from the skin to other parts of the body. BRAF inhibitors and immunotherapy are the standard treatments for...
Read MoreTafinlar vs DTIC in metastatic melanoma; which has better quality-of-life outcomes?
In a nutshell The authors aimed to determine the quality-of-life benefits for metastatic melanoma patients treated with dabrafenib compared to dacarbazine. Some background Metastatic melanoma is melanoma that has spread out to other parts of the body from the primary tumor site. Dabrafenib (Tafinlar) and dacarbazine (DTIC) are drugs used to treat...
Read MoreCan we predict high-intensity focused ultrasound success before treatment?
In a nutshell This paper studied factors that might influence prostate-specific antigen (PSA) nadir levels following high-intensity ultrasound treatment in patients whose cancer has not spread beyond the prostate. Some background High-intensity focused ultrasound (HIFU) is a primary treatment in prostate cancer that targets and removes damaged or...
Read MorePostoperative lymph node radiotherapy versus observation for melanoma patients with a high risk of cancer relapse
In a nutshell The present article evaluated the benefits of adjuvant radiotherapy (RT) compared to observation alone after therapeutic lymphadenectomy (TL) for melanoma patients with a high risk of lymph node relapse (return of cancer to the lymph nodes). Some background Patients with a history of melanoma are at increased risk of developing...
Read More
